BioWorld

Sep. 18, 2008

Biovail Gains Newly Approved HD Drug in $100M Prestwick Buyout

A month after winning FDA approval for its first drug, privately held Prestwick Pharmaceuticals Inc. was acquired by Canadian drugmaker Biovail Corp. in a $100 million deal. (BioWorld Today) Read More

Depomed Starts Hot Flash Phase III for Gabapentin GR

TLR-Independent, Intracellular Innate Immunity Activator Found

FDA Wants More Data for Gilead's CF Infection Drug

Other News To Note

Financings Roundup

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 10, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 10, 2025.

Epigenetic technology could eliminate misfolded prion proteins

BioWorld Science

The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...

CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials

BioWorld

A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...

Brenig Therapeutics discovers new LRRK2 inhibitors

BioWorld Science

Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...